Bingzhong Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bingzhong Zhang has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Ruilin Lei
Department of Gynecologic Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China
3 shared publicationsXiaoting Ling
Department of Gynecology and Obstetrics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, People’s Republic of China
3 shared publicationsGuocai Xu
Department of Gynecologic Oncology, Sun Yat‐sen Memorial Hospital Sun Yat‐sen University Guangzhou People's Republic of China
2 shared publicationsQingjian Li
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangzhou, People’s Republic of China
2 shared publicationsQingsheng Xie
Department of Gynecology and Obstetrics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, People’s Republic of China
2 shared publicationsYun Long
Department of Gynecology and Obstetrics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, People’s Republic of China
2 shared publications
Latest Publications
- Open Access
- 1 May 2026
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 24 (1)
A machine learning framework combining cfDNA fragmentomics and serum biomarkers for early ovarian cancer detection
Ovarian cancer (OC) is a leading cause of cancer-related mortality in women, largely due to the lack of effective strategies for early detection. Here, we
- 1 May 2026
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 24 (1)
Open AccessA machine learning framework combining cfDNA fragmentomics and serum biomarkers for early ovarian cancer detection
Ovarian cancer (OC) is a leading cause of cancer-related mortality in women, largely due to the lack of effective strategies for early detection. Here, we
- Open Access
- 21 July 2024
- Published by Springer Nature in Cancer Cell International
- Vol. 24 (1) , 1-14
Circular RNA circ_ARHGEF28 inhibits MST1/2 dimerization to suppress Hippo pathway to induce cisplatin resistance in ovarian cancer
Background: Cisplatin is integral to ovarian cancer treatment, yet resistance to this drug often results in adverse patient outcomes. The association of circular RNA (circRNA) with cisplatin resistance in ovarian cancer has been observed, but the mechanisms governing this relationship require further elucidation. Methods: High-throughput sequencing was utilized to profile circRNA expression in cisplatin-resistant ovarian cancer cells. Gain-and-loss-of-function experiments assessed the impact on cisplatin sensitivity, both in vitro and in vivo. Fluorescence in situ hybridization was conducted to determine the cellular distribution of circRNAs, and RNA pulldown and immunoprecipitation experiments were performed to identify associated binding proteins. Results: The study revealed that circ_ARHGEF28 is overexpressed in certain cisplatin-resistant ovarian cancer tissues and cell lines, and is associated with reduced progression-free survival in patients. It was observed that circ_ARHGEF28 contributes to cisplatin resistance in ovarian cancer models, both in vitro and in vivo. Importantly, circ_ARHGEF28 was found to interact directly with MST1/2, inhibiting the SARAH coiled-coil binding domains and consequently deactivating the Hippo pathway. Conclusion: This investigation identifies circ_ARHGEF28 as a novel circRNA that contributes to cisplatin resistance in ovarian cancer by suppressing the Hippo pathway. Therapeutic strategies targeting circ_ARHGEF28 may offer a potential avenue to mitigate cisplatin resistance in ovarian cancer treatment.
- 21 July 2024
- Published by Springer Nature in Cancer Cell International
- Vol. 24 (1) , 1-14
Open AccessCircular RNA circ_ARHGEF28 inhibits MST1/2 dimerization to suppress Hippo pathway to induce cisplatin resistance in ovarian cancer
Background: Cisplatin is integral to ovarian cancer treatment, yet resistance to this drug often results in adverse patient outcomes. The association of circular RNA (circRNA) with cisplatin resistance in ovarian cancer has been observed, but the mechanisms governing this relationship require further elucidation. Methods: High-throughput sequencing was utilized to profile circRNA expression in cisplatin-resistant ovarian cancer cells. Gain-and-loss-of-function experiments assessed the impact on cisplatin sensitivity, both in vitro and in vivo. Fluorescence in situ hybridization was conducted to determine the cellular distribution of circRNAs, and RNA pulldown and immunoprecipitation experiments were performed to identify associated binding proteins. Results: The study revealed that circ_ARHGEF28 is overexpressed in certain cisplatin-resistant ovarian cancer tissues and cell lines, and is associated with reduced progression-free survival in patients. It was observed that circ_ARHGEF28 contributes to cisplatin resistance in ovarian cancer models, both in vitro and in vivo. Importantly, circ_ARHGEF28 was found to interact directly with MST1/2, inhibiting the SARAH coiled-coil binding domains and consequently deactivating the Hippo pathway. Conclusion: This investigation identifies circ_ARHGEF28 as a novel circRNA that contributes to cisplatin resistance in ovarian cancer by suppressing the Hippo pathway. Therapeutic strategies targeting circ_ARHGEF28 may offer a potential avenue to mitigate cisplatin resistance in ovarian cancer treatment.
- Open Access
- 12 January 2024
- Published by Springer Nature in Research Square
Circular RNA circ_ARHGEF28 inhibits MST1/2 dimerization to suppress Hippo pathway to induce cisplatin resistance in ovarian cancer
Background: The chemotherapy drug cisplatin is the backbone of the treatment of ovarian cancer, and patients who develop resistance to cisplatin are associated with poor survival. Circular RNA was associated with cisplatin resistance of ovarian cancer.However,the mechanism of interaction between circular RNA and cisplatin resistance of ovarian cancer remains unclear and needs to be further explored. Methods:High-throughput sequencing analysis was performed to identify circRNA expression profiles in cisplatin-resistant ovarian cancer. Gain and loss function experiment were performed to verify the sensitivity of cisplatin in vitro and in vivo. Fluorescence in situ hybridization was performed to demonstrate the cellular location of circRNA.RNA pulldown and RNA immunoprecipitation were were performed to identify the binding protein of circRNA. Result:We found that circ_ARHGEF28 overexpressed in some cisplatin-resistant ovarian cancer tissues and cell lines and was associated with poor PFS in ovarian cancer patients.The circ_ARHGEF28 induced cisplatin resistance in ovarian cancer in vitro and in vivo.Furthermore, circ_ARHGEF28interacted directly with MST1/2 and blocked the SARAH coiled-coil binding domains of MST1/2 to deactivate the Hippo pathway. Conclusion:We identified a novel circular RNA circ_ARHGEF28 induced cisplatin resistance in ovarian cancer by suppressing the Hippo pathway.As a result of our findings, targeting circ_ARHGEF28 may be a potential strategy to overcome cisplatin resistance in ovarian cancer.
- 12 January 2024
- Published by Springer Nature in Research Square
Open AccessCircular RNA circ_ARHGEF28 inhibits MST1/2 dimerization to suppress Hippo pathway to induce cisplatin resistance in ovarian cancer
Background: The chemotherapy drug cisplatin is the backbone of the treatment of ovarian cancer, and patients who develop resistance to cisplatin are associated with poor survival. Circular RNA was associated with cisplatin resistance of ovarian cancer.However,the mechanism of interaction between circular RNA and cisplatin resistance of ovarian cancer remains unclear and needs to be further explored. Methods:High-throughput sequencing analysis was performed to identify circRNA expression profiles in cisplatin-resistant ovarian cancer. Gain and loss function experiment were performed to verify the sensitivity of cisplatin in vitro and in vivo. Fluorescence in situ hybridization was performed to demonstrate the cellular location of circRNA.RNA pulldown and RNA immunoprecipitation were were performed to identify the binding protein of circRNA. Result:We found that circ_ARHGEF28 overexpressed in some cisplatin-resistant ovarian cancer tissues and cell lines and was associated with poor PFS in ovarian cancer patients.The circ_ARHGEF28 induced cisplatin resistance in ovarian cancer in vitro and in vivo.Furthermore, circ_ARHGEF28interacted directly with MST1/2 and blocked the SARAH coiled-coil binding domains of MST1/2 to deactivate the Hippo pathway. Conclusion:We identified a novel circular RNA circ_ARHGEF28 induced cisplatin resistance in ovarian cancer by suppressing the Hippo pathway.As a result of our findings, targeting circ_ARHGEF28 may be a potential strategy to overcome cisplatin resistance in ovarian cancer.
- Open Access
- 7 November 2022
- Published by Wiley in Cancer Medicine
- Vol. 12 (5) , 5409-5419
Application of NGS molecular classification in the diagnosis of endometrial carcinoma: A supplement to traditional pathological diagnosis
Objective: This study aims to demonstrate the advantages of NGS molecular classification in EC diagnosis and to assess whether molecular classification could be performed on curettage specimens and its concordance with subsequent hysterectomy specimens.Methods: 80 patients with hysterectomy specimens and 35/80 patients with paired curettage specimens were stratified as POLE mut, MSI‐H, TP53 wt, or TP53 abn group by NGS panel. Histotype, tumor grade, IHC results, and other pathological details were taken from original pathological reports.Results: The correlation analysis of 80 patients with hysterectomy specimens between NGS molecular classification and clinicopathological characters displayed that the POLE mut group was associated with EEC (87.5%) and TP53 abn subtype was correlated to a later stage (Stage II–IV, 47.6%), G3 (76.2%), serous histology (61.9%) and myometrial invasion ≥50% (47.6%). A favorable concordance (31/32, 96.9%) was shown in MSI analysis and MMR IHC results, and the agreement rate of p53 IHC and TP53 mutation was 81.5% (53/65). Compared with the p53 IHC abnormal group, the TP53 mutation group had a higher correlation with high‐risk factors. A high level of concordance (31/35, 88.0%) of NGS molecular classification was achieved between curettage specimens and hysterectomy specimens while grade and histotype (including unclassified group) from curettage specimens and hysterectomy specimens showed only moderate levels of agreement, 54.3% (19/35) and 68.6% (24/35), respectively.Conclusion: NGS molecular classification achieved on curettage samples showed high concordance with the final hysterectomy specimens, demonstrating superior to the conventional pathological assessment of grade and histotype and potential utilization in clinical practice.
- 7 November 2022
- Published by Wiley in Cancer Medicine
- Vol. 12 (5) , 5409-5419
Open AccessApplication of NGS molecular classification in the diagnosis of endometrial carcinoma: A supplement to traditional pathological diagnosis
Objective: This study aims to demonstrate the advantages of NGS molecular classification in EC diagnosis and to assess whether molecular classification could be performed on curettage specimens and its concordance with subsequent hysterectomy specimens.Methods: 80 patients with hysterectomy specimens and 35/80 patients with paired curettage specimens were stratified as POLE mut, MSI‐H, TP53 wt, or TP53 abn group by NGS panel. Histotype, tumor grade, IHC results, and other pathological details were taken from original pathological reports.Results: The correlation analysis of 80 patients with hysterectomy specimens between NGS molecular classification and clinicopathological characters displayed that the POLE mut group was associated with EEC (87.5%) and TP53 abn subtype was correlated to a later stage (Stage II–IV, 47.6%), G3 (76.2%), serous histology (61.9%) and myometrial invasion ≥50% (47.6%). A favorable concordance (31/32, 96.9%) was shown in MSI analysis and MMR IHC results, and the agreement rate of p53 IHC and TP53 mutation was 81.5% (53/65). Compared with the p53 IHC abnormal group, the TP53 mutation group had a higher correlation with high‐risk factors. A high level of concordance (31/35, 88.0%) of NGS molecular classification was achieved between curettage specimens and hysterectomy specimens while grade and histotype (including unclassified group) from curettage specimens and hysterectomy specimens showed only moderate levels of agreement, 54.3% (19/35) and 68.6% (24/35), respectively.Conclusion: NGS molecular classification achieved on curettage samples showed high concordance with the final hysterectomy specimens, demonstrating superior to the conventional pathological assessment of grade and histotype and potential utilization in clinical practice.
- Open Access
- 7 May 2021
- Published by Springer Nature in Cancer Cell International
- Vol. 21 (1) , 1-14
HHLA2 predicts better survival and exhibits inhibited proliferation in epithelial ovarian cancer
Purpose: The role of HHLA2, a new immune checkpoint ligand, is gradually being elucidated in various solid tumours. However, its role in ovarian cancer remains unclear; thus, its expression profile and clinical significance in ovarian cancer must be examined. Methods: We performed immunohistochemistry to examine HHLA2 expression in 64 ovarian cancer tissues and 16 normal ovarian tissues. The relationships between HHLA2 expression and clinicopathological features, prognosis, and CD8+ tumour-infiltrating lymphocytes (TILs) in patients were analysed. Additionally, the Cancer Cell Line Encyclopedia database was used to analyse the correlation between HHLA2 expression and PD-L1 or B7x expression. Furthermore, the biological function of HHLA2 in ovarian cancer cells was initially explored. Results: Only 17.2% of ovarian cancer patients showed HHLA2 expression, which was significantly associated with the differentiation of ovarian cancer cells (p = 0.027), and well-differentiated tumours expressed higher levels of HHLA2. The density of CD8+ TIL was associated with increased HHLA2 expression (p = 0.017), and the CD8+ TIL count was higher in the HHLA2-positive group than that in the HHLA2-negative group (p = 0.023). Moreover, multivariate analysis identified HHLA2 expression as an independent prognostic factor that predicted improved survival (p = 0.049; HR = 0.156; 95% CI = 0.025–0.992). Additionally, we also found that overexpressing HHLA2 inhibited the proliferation of ovarian cancer cells. Conclusion: HHLA2 is associated with tumour differentiation and high CD8+ TIL levels; and predicts improved survival in ovarian cancer. Along with previously reported findings that HHLA2 behaves as a co-stimulatory ligand, our study suggests that the loss of HHLA2 may contribute to the immunosuppressive microenvironment and progression of ovarian cancer.
- 7 May 2021
- Published by Springer Nature in Cancer Cell International
- Vol. 21 (1) , 1-14
Open AccessHHLA2 predicts better survival and exhibits inhibited proliferation in epithelial ovarian cancer
Purpose: The role of HHLA2, a new immune checkpoint ligand, is gradually being elucidated in various solid tumours. However, its role in ovarian cancer remains unclear; thus, its expression profile and clinical significance in ovarian cancer must be examined. Methods: We performed immunohistochemistry to examine HHLA2 expression in 64 ovarian cancer tissues and 16 normal ovarian tissues. The relationships between HHLA2 expression and clinicopathological features, prognosis, and CD8+ tumour-infiltrating lymphocytes (TILs) in patients were analysed. Additionally, the Cancer Cell Line Encyclopedia database was used to analyse the correlation between HHLA2 expression and PD-L1 or B7x expression. Furthermore, the biological function of HHLA2 in ovarian cancer cells was initially explored. Results: Only 17.2% of ovarian cancer patients showed HHLA2 expression, which was significantly associated with the differentiation of ovarian cancer cells (p = 0.027), and well-differentiated tumours expressed higher levels of HHLA2. The density of CD8+ TIL was associated with increased HHLA2 expression (p = 0.017), and the CD8+ TIL count was higher in the HHLA2-positive group than that in the HHLA2-negative group (p = 0.023). Moreover, multivariate analysis identified HHLA2 expression as an independent prognostic factor that predicted improved survival (p = 0.049; HR = 0.156; 95% CI = 0.025–0.992). Additionally, we also found that overexpressing HHLA2 inhibited the proliferation of ovarian cancer cells. Conclusion: HHLA2 is associated with tumour differentiation and high CD8+ TIL levels; and predicts improved survival in ovarian cancer. Along with previously reported findings that HHLA2 behaves as a co-stimulatory ligand, our study suggests that the loss of HHLA2 may contribute to the immunosuppressive microenvironment and progression of ovarian cancer.